货号：DT2025061309
CAS：1189878-76-9
规格：mg(更多包装需求请咨询客服)
纯度：≥98%
生产商：试剂家

生物活性：Zileuton-d4 is the deuterium labeled Zileuton. Zileuton (A 64077) is a potent and selective inhibitor of 5-lipoxygenase with antiasthmatic properties[1][2].
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
试剂家 has not independently confirmed the accuracy of these methods. They are for reference only.
Zileuton-d4 相关抗体:
Ferritin Heavy Chain Antibody
AMID/FSP1 Antibody
Peroxiredoxin 1 Antibody (YA692)
PRDX3 Antibody (YA909)
LOX 1 Antibody
5 Lipoxygenase Antibody (YA1937)
12 Lipoxygenase Antibody (YA2038)
Ferritin Light Chain Antibody (YA971)
Ferritin Light Chain Antibody (YA972)
15 Lipoxygenase 1 Antibody (YA1091)
ALOX15 Antibody (YA1309)
分子量：240.31
Formula：C11H8D4N2O2S
CAS 号：1189878-76-9
非标记 CAS：111406-87-2
中文名称：齐留通 d4
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (531 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Abueid L, et al. Inhibition of 5-lipoxygenase by zileuton in a rat model of myocardial infarction. Anatol J Cardiol. 2016 Nov 10
 [Content Brief]
[3]. Kuvibidila S, et al. Hydroxyurea and Zileuton Differentially Modulate Cell Proliferation and Interleukin-2 Secretion by Murine Spleen Cells: Possible Implication on the Immune Function and Risk of Pain Crisis in Patients with Sickle Cell Disease. Ochsner
 [Content Brief]
[4]. Gounaris E, et al. Zileuton, 5-lipoxygenase inhibitor, acts as a chemopreventive agent in intestinal polyposis, by modulating polyp and systemic inflammation. PLoS One. 2015 Mar 6;10(3):e0121402
 [Content Brief]